|
000
| 02399nam 2200409zi 4500 |
|---|
| 001 | 9.927743 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20231130151823 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 230925e202311 onc o f000 0 eng d |
|---|
| 020 | |a9780660680651 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-305/2023E-1-PDF |
|---|
| 245 | 00|aGuidance document : |bcertificates of supplementary protection. |
|---|
| 246 | 17|aCSP guidance document |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cNovember 2023. |
|---|
| 264 | 4|c©2023 |
|---|
| 300 | |a1 online resource (25 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : certificats de protection supplémentaire. |
|---|
| 500 | |aCover title. |
|---|
| 500 | |a"Date adopted: 2017/09/21; Revised Date: 22023/11/16; Effective date: 2023/11/16." |
|---|
| 520 | |a"In agreeing to apply the Canada-European Union Comprehensive Economic and Trade Agreement (CETA), Canada has committed to provide up to two years of sui generis (of its own kind) protection for new pharmaceutical products protected by an eligible patent, from the expiry of the patent. Canada has implemented this commitment by introducing Certificates of Supplementary Protection (CSPs) for medicinal ingredients, applicable for Canadian pharmaceuticals, biologics and veterinary drugs. … The purpose of this Guidance Document is to outline the CSP application process for applicants, the service standard and the roles and responsibilities of applicants and Health Canada"--Introduction, page 7. |
|---|
| 650 | 0|aPatent medicines|zCanada. |
|---|
| 650 | 0|aPatent extensions|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLigne directrice : |w(CaOODSP)9.927744 |
|---|
| 794 | |tGuidance document : |w(CaOODSP)9.931029 |
|---|
| 795 | |tGuidance document : |w9.921627 |
|---|
| 856 | 40|qPDF|s467 KB|uhttps://publications.gc.ca/collections/collection_2023/sc-hc/H164-305-2023-1-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/register-certificates/certificate-supplementary-protection-regulations.html |
|---|